BRAINSTORM CELL THERAPEUTICS INC. Increase (Decrease) in Accounts Payable
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Increase (Decrease) in Accounts Payable of $171.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $171.00K.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $250.00K, a 65.13% decline year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2025-06-30 was -$800.00K.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2025-03-31 was $717.00K.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accounts payable for fiscal 2022 was $2.52M.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accounts payable for fiscal 2021 was -$1.72M.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accounts payable for fiscal 2020 was -$9.26M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|
| 2026-06-30 | $171.00K 10-Q · filed 2026-08-14 | $421.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $250.00K 10-Q · filed 2026-05-15 | ||
| 2025-06-30 | -$800.00K 10-Q · filed 2026-08-14 | -$83.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $717.00K 10-Q · filed 2026-05-15 | ||
| 2022-12-31 | $2.52M 10-K · filed 2023-03-30 | ||
| 2021-12-31 | -$1.72M 10-K · filed 2023-03-30 | ||
| 2020-12-31 | -$9.26M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |